Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 11/20 | 0.63 |
| ▸ | FAAH | O00519 | 11/20 | 0.63 |
| ▸ | CES2 | O00748 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794313 | 1.00 | CES1 (0.63) | CES1FAAHCES2MEN1CYP1A2 | |
| SCHEMBL2897766 | 0.89 | FAAH (0.70) | CES1FAAHMEN1CYP1A2KMT2A | |
| SCHEMBL2897767 | 0.89 | FAAH (0.70) | CES1FAAHMEN1CYP1A2KMT2A | |
| SCHEMBL14886368 | 0.84 | CES1 (0.55) | CES1FAAHCES2MEN1CYP1A2 | |
| SCHEMBL31550553 | 0.83 | CES1 (0.58) | CES1FAAHCES2MEN1CYP1A2 | |
| SCHEMBL5514001 | 0.80 | CES2 (0.65) | CES1CES2MEN1KMT2AHSD17B10 | |
| SCHEMBL28700622 | 0.79 | CES1 (0.52) | CES1FAAHCES2MEN1CYP1A2 | |
| SCHEMBL1692355 | 0.78 | CES2 (1.00) | CES1CES2MEN1KMT2AHSD17B10 | |
| SCHEMBL11438920 | 0.78 | CES2 (1.00) | CES1CES2MEN1KMT2AHSD17B10 | |
| SCHEMBL14351405 | 0.78 | CES2 (1.00) | CES1CES2MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150338425-A1 | TREATMENT AND PROGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-11-26 | — | — | US | claimed |
| WO-2013074583-A1 | TREATMENT AND PROGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS | THE BROAD INSTITUTE, INC. (US) | 2013-05-23 | — | — | WO | claimed |
| EP-1747003-A4 | PHOSPHOLIPASE INHIBITORS LOCALIZED IN THE GASTROINTESTINAL LUMEN | ILYPSA INC (US) | 2008-01-09 | — | — | EP | claimed |
| US-20070292385-A1 | Phospholipase Inhibitors Localized in the Gastrointestinal Lumen | ILYPSA, INC. | 2007-12-20 | — | — | US | claimed |
| EP-1747003-A1 | PHOSPHOLIPASE INHIBITORS LOCALIZED IN THE GASTROINTESTINAL LUMEN | Ilypsa, Inc. (US) | 2007-01-31 | — | — | EP | claimed |
| US-20060058225-A1 | Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease | MCGILL UNIVERSITY | 2006-03-16 | — | — | US | claimed |
| WO-2005107766-A1 | PHOSPHOLIPASE INHIBITORS LOCALIZED IN THE GASTROINTESTINAL LUMEN | ILYPSA, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050244367-A1 | Phospholipase inhibitors localized in the gastrointestinal lumen | ILYPSA, INC. (US) | 2005-11-03 | — | — | US | claimed |
| EP-1509247-A1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT, PREVENTION OR DIAGNOSIS OF NEURAL INFLAMMATORY OR DEMYELINATING DIESEASES | McGILL UNIVERSITY (CA) | 2005-03-02 | — | — | EP | claimed |
| WO-2003101487-A1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT, PREVENTION OR DIAGNOSIS OF NEURAL INFLAMMATORY OR DEMYELINATING DISEASE | MCGILL UNIVERSITY (CA) | 2003-12-11 | — | — | WO | claimed |
| US-20030225011-A1 | Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease | MCGILL UNIVERSITY (CA) | 2003-12-04 | — | — | US | claimed |
| WO-2022202099-A1 | METHOD FOR TESTING FOR INFLAMMATORY BOWEL DISEASE | 国立大学法人大阪大学 | 2022-09-29 | — | — | WO | disclosed |
| US-20150338425-A1 | TREATMENT AND PROGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-11-26 | — | — | US | disclosed |
| WO-2013074583-A1 | TREATMENT AND PROGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS | THE BROAD INSTITUTE, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20110280807-A1 | Methods and Models for Stress-Induced Analgesia | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-5994398-A | ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5866318-A | Inhibition of phospholipase A2 to reduce neuronal cell death | ATHENA NEUROSCIENCES, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998025893-A1 | ARYLSULFONAMIDES AS PHOSPHOLIPASE A2 INHIBITORS | ATHENA NEUROSCIENCES, INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5707821-A | Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease | ATHENA NEUROSCIENCES, INC. (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1996040982-A1 | THERAPEUTIC INHIBITION OF PHOSPHOLIPASE A2 IN NEURODEGENERATIVE DISEASE | ATHENA NEUROSCIENCES, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050244367-A1 | Phospholipase inhibitors localized in the gastrointestinal lumen | PNLIP, PLA2G2E, PLA2G4B | CES1 76/4885FAAH 142/4885CES2 528/4885 |
| US-20070292385-A1 | Phospholipase Inhibitors Localized in the Gastrointestinal Lumen | PNLIP, PLA2G2E, PLA2G4B | CES1 76/4885FAAH 142/4885CES2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.